These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7804950)

  • 1. Drug therapy for hypertension: where we are, and where we might be heading.
    Wilson TW; Quest DW
    Can J Public Health; 1994; 85 Suppl 2():S48-50. PubMed ID: 7804950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and trends in the drug treatment of essential hypertension.
    van Zwieten PA
    J Hypertens Suppl; 1992 Dec; 10(7):S1-12. PubMed ID: 1363322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological basis of antihypertensive drug therapy].
    Kolck UW; Zaugg CE; Erne P
    Praxis (Bern 1994); 2004 May; 93(20):847-56. PubMed ID: 15195836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system.
    Sim JJ; Bhandari SK; Shi J; Kalantar-Zadeh K; Rasgon SA; Sealey JE; Laragh JH
    Am J Hypertens; 2012 Mar; 25(3):379-88. PubMed ID: 22158065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
    Shimosawa T
    Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blockers for management of hypertension.
    Catanzaro DF; Frishman WH
    South Med J; 2010 Jul; 103(7):669-73. PubMed ID: 20531060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in antihypertensive treatment--lessons from the National Acute Stroke Israeli (NASIS) registry.
    Koifman E; Tanne D; Molshatzki N; Leibowitz A; Grossman E
    Blood Press; 2014 Oct; 23(5):262-9. PubMed ID: 24483945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approach to Antihypertensive Therapy.
    Reddy P; Dupree L
    Am J Ther; 2016; 23(2):e451-73. PubMed ID: 25719531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraclass differences among antihypertensive drugs.
    Feldman RD; Hussain Y; Kuyper LM; McAlister FA; Padwal RS; Tobe SW
    Annu Rev Pharmacol Toxicol; 2015; 55():333-52. PubMed ID: 25251994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure reduction is not the only determinant of outcome.
    Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR; Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR
    Circulation; 2006 Jun; 113(23):2754-72; discussion 2773-4. PubMed ID: 16769926
    [No Abstract]   [Full Text] [Related]  

  • 13. Antihypertensive drugs.
    Laurent S
    Pharmacol Res; 2017 Oct; 124():116-125. PubMed ID: 28780421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of antihypertensive treatment.
    Arnett DK; Claas SA; Glasser SP
    Vascul Pharmacol; 2006 Feb; 44(2):107-18. PubMed ID: 16356784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.
    Unger T; Paulis L; Sica DA
    Eur Heart J; 2011 Nov; 32(22):2739-47. PubMed ID: 21951628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive persistence and drug class.
    Marentette MA; Gerth WC; Billings DK; Zarnke KB
    Can J Cardiol; 2002 Jun; 18(6):649-56. PubMed ID: 12107422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Renin-angiotensin-aldosterone system inhibition: pharmacologic rationale and evaluations of drug combinations].
    Andréjak M; Slama M; Hary L
    Therapie; 1998; 53(3):291-300. PubMed ID: 9773129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
    JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic Issues in treating hypertension in CKD.
    Sica DA
    Adv Chronic Kidney Dis; 2011 Jan; 18(1):42-7. PubMed ID: 21224029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.